Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

07-12-2013 | Colorectal cancer | Book chapter | Article

38. Colorectal Cancer

Authors: Roberto García-Figueiras, MD, Sandra Baleato-González, MD, Antonio Gómez-Caamaño, MD, Ana Alvarez-Castro, MD, Jesús Paredes-Cotoré, MD, PhD

Publisher: Springer Berlin Heidelberg

Login to get access

Abstract

Functional and molecular imaging techniques have a growing role in colorectal cancer. These techniques may be useful tools in the process of management of patients with colorectal cancer including diagnosis, prognosis, planning therapy, and assessment of response to treatment. In addition, this chapter will review recent developments in imaging technologies, validation of these newer imaging techniques, evolving roles for these techniques, and challenges for their implementation.
Literature
1.
Bipat S, et al. Imaging modalities for the staging of patients with colorectal cancer. Neth J Med. 2012;70:26–34.PubMed
2.
Liang TY, et al. Imaging paradigms in assessment of rectal carcinoma: loco-regional and distant staging. Cancer Imaging. 2012;12:290–303.PubMedCrossRef
3.
Kosinski L, et al. Shifting concepts in rectal cancer management: a review of contemporary primary rectal cancer treatment strategies. CA Cancer J Clin. 2012;62:173–202.PubMedCrossRef
4.
Torkzad MR, et al. Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review. Insights Imaging. 2010;1:245–67.PubMedCentralPubMedCrossRef
5.
Hanahan D, Weinberg RA. The hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRef
6.
Kapse N, Goh V. Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography. Clin Colorectal Cancer. 2009;8:77–87.CrossRef
7.
Goh V, et al. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol. 2007;8:245–55.PubMedCrossRef
8.
Figueiras RG et al. The role of functional imaging in colorectal cancer. AJR Am J Roentgenol. 2010;195:54–66.PubMedCrossRef
9.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRef
10.
Cairns RA, et al. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.PubMedCrossRef
11.
Moreno-Sánchez R, et al. Energy metabolism in tumor cells. FEBS J. 2007;274:1393–418.PubMedCrossRef
12.
Herbertson RA, et al. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol. 2009;64:225–37.PubMedCrossRef
13.
Lin M. Molecular imaging using positron emission tomography in colorectal cancer. Discov Med. 2011;11:435–47.PubMed
14.
Patel S, et al. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg. 2011;253:666–71.PubMedCrossRef
15.
Schmoll HJ, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.PubMedCrossRef
16.
Davey K, et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum. 2008;51:997–1003.PubMedCrossRef
17.
Bipat S, et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging – a meta-analysis. Radiology. 2004;232:773–83.PubMedCrossRef
18.
Llamas-Elvira J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:859–67.PubMedCrossRef
19.
Guerra L, et al. Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging. 2011;36:38–45.PubMedCrossRef
20.
Capirci C, et al. Sequential FDGPET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1583–93.PubMedCrossRef
21.
Kalff V, et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 2006;47:14–22.PubMed
22.
Chen LB, et al. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2011;13:5025–9.
23.
Bassi MC, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys. 2008;70:1423–6.PubMedCrossRef
24.
Huebner RH, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177–89.PubMed
25.
Deleau C, et al. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence. Eur J Gastroenterol Hepatol. 2011;23:275–81.PubMedCrossRef
26.
Kim MJ, et al. Detection of rectal cancer and response to concurrent chemoradiotherapy by proton magnetic resonance spectroscopy. Magn Reson Imaging. 2012;30:848–53.PubMedCrossRef
27.
Dzik-Jurasz AS, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med. 2002;47:809–11.PubMedCrossRef
28.
Francis DL, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52:1602–6.PubMedCrossRef
29.
Roels S, et al. Biological image guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol. 2008;47:1237–48.PubMedCrossRef
30.
Muijs CT, et al. 18F-FLT-PET for detection of rectal cancer. Radiother Oncol. 2011;98:357–9.PubMedCrossRef
31.
Wieder H, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878–83.PubMedCrossRef
32.
Padhani AR, et al. Diffusion- weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102–25.PubMedCentralPubMed
33.
Ichikawa T, et al. High-B-value diffusion weighted MRI in colorectal cancer. AJR Am J Roentgenol. 2006;187:181–4.PubMedCrossRef
34.
Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010;254:47–66.PubMedCrossRef
35.
Mizukami Y, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer. World J Surg. 2011;35:895–9.PubMedCrossRef
36.
Lambregts DM, et al. Whole-body diffusion-weighted magnetic resonance imaging: current evidence in oncology and potential role in colorectal cancer staging. Eur J Cancer. 2011;47:2107–16.PubMedCrossRef
37.
Curvo-Semedo L, et al. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging. 2012;35:1365–71.PubMedCrossRef
38.
Dzik-Jurasz A, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet. 2002;360:307–8.PubMedCrossRef
39.
Jung SH, et al. Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging. 2012;35:110–6.PubMedCrossRef
40.
Barbaro B, et al. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:594–9.PubMed
41.
Park MJ, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology. 2011;260:771–80.PubMedCrossRef
42.
Padhani AR, Koh DM. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am. 2011;19:181–209.PubMedCrossRef
43.
Hein PA, et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol. 2003;45:214–22.PubMedCrossRef
44.
Lambregts DM, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol. 2011;18:2224–31.PubMedCentralPubMedCrossRef
45.
Curvo-Semedo L, et al. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy–conventional MR volumetry versus diffusion-weighted MR imaging. Radiology. 2011;260:734–43.PubMedCrossRef
46.
Kim SH, et al. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol. 2011;21:987–95.PubMedCrossRef
47.
Engin G, et al. Can diffusion-weighted MRI determine complete responders after neoadjuvant chemoradiation for locally advanced rectal cancer? Diagn Interv Radiol. 2012;18:574–81.PubMed
48.
Song I, et al. Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging. Br J Radiol. 2012;85:577–86.PubMedCrossRef
49.
Lambregts DM, et al. Value of ADC measurements for nodal staging after chemoradiation in locally advanced rectal cancer-a per lesion validation study. Eur Radiol. 2011;21:265–73.PubMedCentralPubMedCrossRef
50.
Colosio A, et al. Local colorectal cancer recurrence: pelvic MRI evaluation. Abdom Imaging. 2013;38:72–81.PubMedCrossRef
51.
Lambregts DM, et al. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol. 2011;21:1250–8.PubMedCentralPubMedCrossRef
52.
Koh DM, et al. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol. 2011;196:1351–61.PubMedCrossRef
53.
Bäuerle T, et al. Diffusion-weighted imaging in rectal carcinoma patients without and after chemoradiotherapy: a comparative study with histology. Eur J Radiol. 2013;82:444–52.PubMedCrossRef
54.
Turkbey B, et al. Imaging of tumor angiogenesis: functional or targeted? AJR Am J Roentgenol. 2009;193:304–13.PubMedCentralPubMedCrossRef
55.
Kierkels RG, et al. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in rectal cancer. Int J Radiat Oncol Biol Phys. 2010;77:400–8.PubMedCrossRef
56.
García-Figueiras R, et al. CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol. 2013;200:8–19.PubMedCrossRef
57.
Dighe S, et al. Perfusion CT to assess angiogenesis in colon cancer: technical limitations and practical challenges. Br J Radiol. 2012;85:e814–25.PubMedCrossRef
58.
Sahani DV, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology. 2005;234:785–92.PubMedCrossRef
59.
Feng ST, et al. Evaluation of angiogenesis in colorectal carcinoma with multidetector-row CT multislice perfusion imaging. Eur J Radiol. 2010;75:191–6.PubMedCrossRef
60.
Khan S, et al. Perfusion CT assessment of the colon and rectum: feasibility of quantification of bowel wall perfusion and vascularization. Eur J Radiol. 2012;81:821–4.PubMedCrossRef
61.
Goh V, et al. Differentiation between diverticulitis and colorectal cancer: quantitative CT perfusion measurements versus morphologic criteria – initial experience. Radiology. 2007;242:456–62.PubMedCrossRef
62.
Goh V, et al. Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol. 2009;19:79–89.PubMedCrossRef
63.
Hayano K, et al. Quantitative measurement of blood flow using perfusion CT for assessing clinicopathologic features and prognosis in patients with rectal cancer. Dis Colon Rectum. 2009;52:1624–9.PubMedCrossRef
64.
Bellomi M, et al. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology. 2007;244:486–93.PubMedCrossRef
65.
Curvo-Semedo L, et al. Usefulness of perfusion CT to assess response to neoadjuvant combined chemoradiotherapy in patients with locally advanced rectal cancer. Acad Radiol. 2012;19:203–13.PubMedCrossRef
66.
Anzidei M, et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr. 2011;35:690–6.PubMedCrossRef
67.
Janssen MH, et al. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol. 2010;94:156–60.PubMedCrossRef
68.
Zhang XM, et al. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis. J Magn Reson Imaging. 2008;27:1309–16.PubMedCrossRef
69.
Morgan B, et al. Dynamic contrast enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21:3955–64.PubMedCrossRef
70.
Mross K, et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res. 2009;1:5.PubMedCentralPubMedCrossRef
71.
Lim JS, et al. Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer. Eur Radiol. 2012;22:1693–700.PubMedCrossRef
72.
George ML, et al. Non- invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001;88:1628–36.PubMedCrossRef
73.
Hirashima Y, et al. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of Bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer. 2012;130:2359–65.PubMedCrossRef
74.
Onji K, et al. Microvascular structure and perfusion imaging of colon cancer by means of contrast-enhanced ultrasonography. Abdom Imaging. 2012;37:297–303.PubMedCrossRef
75.
Meijerink MR, et al. Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities. Ultrasound Med Biol. 2010;36:1626–36.PubMedCrossRef
76.
Wu L, et al. Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: a meta-analysis. Eur J Radiol. 2011;80:582–9.PubMedCrossRef
77.
Froehlich JM, et al. Does quantification of USPIO uptake-related signal loss allow differentiation of benign and malignant normal-sized pelvic lymph nodes? Contrast Media Mol Imaging. 2012;7:346–55.PubMedCrossRef
78.
Lahaye MJ, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology. 2008;246:804–11.PubMedCrossRef
79.
Thoeny HC, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761–9.PubMedCrossRef
80.
Padhani AR, et al. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861–72.PubMedCentralPubMedCrossRef
81.
Mees G, et al. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging. 2009;36:1674–86.PubMedCentralPubMedCrossRef
82.
O’Connor JP, et al. Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys. 2009;75:1209–15.PubMedCrossRef
83.
Havelund BM, et al. Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun. 2013;34:155–61.PubMedCrossRef
84.
Yang SY, et al. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med. 2009;15:225–33.PubMedCrossRef
85.
Keen HG, et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol. 2005;32:395–402.PubMedCrossRef
86.
Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256:348–64.PubMedCrossRef
87.
Ono K, et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging. 2009;29:336–40.PubMedCrossRef
88.
Gu J, et al. Combined use of 18F-FDG PET/CT, DW-MRI, and DCE-MRI in treatment response for preoperative chemoradiation therapy in locally invasive rectal cancers. Clin Nucl Med. 2013;38:e226–9.PubMedCrossRef
89.
Goh V, et al. The flow-metabolic phenotype of primary colorectal cancer: assessment by integrated 18F-FDG PET/perfusion CT with histopathologic correlation. J Nucl Med. 2012;53:687–92.PubMedCrossRef
90.
Gu J, et al. Dynamic contrast-enhanced MRI of primary rectal cancer: quantitative correlation with positron emission tomography/computed tomography. J Magn Reson Imaging. 2011;33:340–7.PubMedCrossRef
91.
Gu J, et al. Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. Mol Imaging Biol. 2011;13:1020–8.PubMedCentralPubMedCrossRef
92.
Miles KA, et al. Demonstrating intertumoural differences in vascular-metabolic phenotype with dynamic contrast-enhanced CT-PET. Int J Mol Imaging. 2011;2011:679473.PubMedCentralPubMedCrossRef
93.
Van Laarhoven HWM, et al. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys. 2006;64:473–82.PubMedCrossRef
94.
Yong TW, et al. Sensitivity of PET/MR images in liver metastases from colorectal carcinoma. Hell J Nucl Med. 2011;14:264–8.PubMed
95.
De Bruyne S, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with Bevacizumab for colorectal liver metastases. Br J Cancer. 2012;106:1926–33.PubMedCentralPubMedCrossRef
96.
Willett CG, et al. Direct evidence that the VEGF-specific antibody Bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145–7.PubMedCentralPubMedCrossRef
97.
Figueiras RG, et al. Novel oncologic drugs: what they do and how they affect images. Radiographics. 2011;31:2059–91.PubMedCrossRef
98.
Goh V, et al. Integrated (18)F-FDG PET/CT and perfusion CT of primary colorectal cancer: effect of inter- and intraobserver agreement on metabolic-vascular parameters. AJR Am J Roentgenol. 2012;199:1003–9.PubMedCrossRef
99.
Ng F, et al. Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. Radiology. 2013;266:177–84.PubMedCrossRef
Image Credits